结直肠癌组织中ARID1A基因突变及DEPDC1表达与临床病理特征及预后的相关性

Correlation of ARID1A gene mutation and DEPDC1 expression in colorectal cancer tissues with clinicopathological features and prognosis of patients

目的探讨结直肠癌中ARID1A基因突变及DEPDC1表达与患者临床病理特征及预后的相关性。方法回顾性分析2017年5月至2019年5月漯河市中心医院收治的152例结直肠癌患者的临床资料,所有患者均采用测序分析法和BCA法分析癌组织样本中ARID1A基因的突变情况和DEPDC1的蛋白表达水平,依据ARID1A基因的突变情况和DEPDC1的蛋白表达水平分为ARID1A基因突变组、ARID1A基因未突变组和DEPDC1高表达组、DEPDC1低表达组,并评估ARID1A基因突变、DEPDC1表达与肿瘤的淋巴结转移、临床分期、大小和病理分化等临床病理特征的关系。使用Kaplan-Meier生存曲线分析ARID1A基因突变及DEPDC1高表达对患者5年生存率的影响。结果ARID1A基因突变组患者的低分化占比、Ⅲ~Ⅳ期占比、脉管侵犯占比均为63.64%(21/33)、54.55%(18/33)和60.61(20/33),明显高于ARID1A基因未突变组的29.41%(35/119)、24.37%(29/119)和31.93%(38/119),差异均有统计学意义(P<0.05);DEPDC1高表达组患者的Ⅲ~Ⅳ期占比、淋巴转移占比分别为46.51%(20/43)、53.49%(23/43),明显高于DEPDC1低表达组的24.77%(27/109)、24.77%(27/109),差异均有统计学意义(P<0.05);Kaplan-Meier生存分析结果显示,ARID1A基因未突变和DEPDC1低表达的患者5年生存率分别为70.59%和84.40%,明显高于ARID1A基因突变患者的39.39%和DEPDC1高表达患者的48.84%,差异均有统计学意义(P<0.05)。结论ARID1A基因突变及DEPDC1高表达可能在结直肠癌的发展和预后中发挥作用,为结直肠癌的分子分类和个体化治疗提供潜在的靶点。

Objective To investigate the correlation of ARID1A gene mutation and DEPDC1 expression with the clinicopathological features and prognosis of colorectal cancer patients.Methods A retrospective analysis was conducted on the clinical data of 152 colorectal cancer patients treated at Luohe Central Hospital from May 2017 to May 2019.All patients underwent sequencing analysis and bicinchonininc acid(BCA)method to determine the mutation status of the ARID1A gene and the protein expression levels of DEPDC1 in cancer tissue samples.Patients were categorized into groups based on ARID1A gene mutation status(mutated and nonmutated)and DEPDC1 expression levels(high and low).The relationships of ARID1A gene mutations,DEPDC1 expression with various clinicopathological features such as lymph node metastasis,clinical staging,tumor size,and pathological differentiation were assessed.The impact of ARID1A gene mutations and high DEPDC1 expression on 5year survival rates was analyzed using KaplanMeier survival curves.Results The proportions of patients with poor differentiation,stageⅢⅣ,and vascular invasion were 63.64%(21/33),54.55%(18/33),and 60.61(20/33)in patients with ARID1A gene mutations,significantly higher than 29.41%(35/119),24.37%(29/119),and 31.93%(38/119)in patients without ARID1A gene mutations(P<0.05).The proportions of patients with stageⅢⅣand lymph node metastasis were 46.51%(20/43)and 53.49%(23/43)in patients with high expression of DEPDC1,respectively,which were significantly higher than 24.77%(27/109)and 24.77%(27/109)in patients with low expression of DEPDC1(P<0.05).KaplanMeier survival analysis revealed that patients without ARID1A gene mutations and those with low DEPDC1 expression had significantly higher 5year survival rates(70.59%and 84.40%,respectively),compared to 39.39%for patients with ARID1A gene mutations and 48.84%for those with high DEPDC1 expression(P<0.05).Conclusion ARID1A gene mutations and high DEPDC1 expression may play roles in the progression and prognosis of colorectal cancer,providing potential targets for molecular classification and personalized treatment of this disease.